148 related articles for article (PubMed ID: 32241247)
1. Exploring the interaction of Peloruside-A with drug resistant αβII and αβIII tubulin isotypes in human ovarian carcinoma using a molecular modeling approach.
Kumbhar BV; Bhandare VV
J Biomol Struct Dyn; 2021 Apr; 39(6):1990-2002. PubMed ID: 32241247
[TBL] [Abstract][Full Text] [Related]
2. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.
Kanakkanthara A; Northcote PT; Miller JH
Mol Cancer Ther; 2012 Feb; 11(2):393-404. PubMed ID: 22180309
[TBL] [Abstract][Full Text] [Related]
3. Delineating the interaction of combretastatin A-4 with αβ tubulin isotypes present in drug resistant human lung carcinoma using a molecular modeling approach.
Kumbhar BV; Bhandare VV; Panda D; Kunwar A
J Biomol Struct Dyn; 2020 Feb; 38(2):426-438. PubMed ID: 30831055
[TBL] [Abstract][Full Text] [Related]
4. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.
Kanakkanthara A; Wilmes A; O'Brate A; Escuin D; Chan A; Gjyrezi A; Crawford J; Rawson P; Kivell B; Northcote PT; Hamel E; Giannakakou P; Miller JH
Mol Cancer Ther; 2011 Aug; 10(8):1419-29. PubMed ID: 21653684
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Origin of Differential Binding Affinities of Human Tubulin Isotypes αβII, αβIII and αβIV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations.
Kumbhar BV; Borogaon A; Panda D; Kunwar A
PLoS One; 2016; 11(5):e0156048. PubMed ID: 27227832
[TBL] [Abstract][Full Text] [Related]
6. Interaction of microtubule depolymerizing agent indanocine with different human αβ tubulin isotypes.
Kumbhar BV; Panda D; Kunwar A
PLoS One; 2018; 13(3):e0194934. PubMed ID: 29584771
[TBL] [Abstract][Full Text] [Related]
7. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
[TBL] [Abstract][Full Text] [Related]
8. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
Wang W; Zhang H; Wang X; Patterson J; Winter P; Graham K; Ghosh S; Lee JC; Katsetos CD; Mackey JR; Tuszynski JA; Wong GK; Ludueña RF
Protoplasma; 2017 May; 254(3):1163-1173. PubMed ID: 27943021
[TBL] [Abstract][Full Text] [Related]
9. Computational study of interactions of anti-cancer drug eribulin with human tubulin isotypes.
Rai K; Kumbhar BV; Panda D; Kunwar A
Phys Chem Chem Phys; 2022 Jul; 24(27):16694-16700. PubMed ID: 35766982
[TBL] [Abstract][Full Text] [Related]
10. Structural insight into the role of Gln293Met mutation on the Peloruside A/Laulimalide association with αβ-tubulin from molecular dynamics simulations, binding free energy calculations and weak interactions analysis.
Zúñiga MA; Alderete JB; Jaña GA; Jiménez VA
J Comput Aided Mol Des; 2017 Jul; 31(7):643-652. PubMed ID: 28597356
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling study on the differential microtubule-stabilizing effect in singly- and doubly-bonded complexes with peloruside A and paclitaxel.
Zúñiga MA; Alderete JB; Jaña GA; Navarrete KR; Jiménez VA
Proteins; 2019 Aug; 87(8):668-678. PubMed ID: 30958582
[TBL] [Abstract][Full Text] [Related]
12. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.
Gaitanos TN; Buey RM; Díaz JF; Northcote PT; Teesdale-Spittle P; Andreu JM; Miller JH
Cancer Res; 2004 Aug; 64(15):5063-7. PubMed ID: 15289305
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to peloruside A and laulimalide is associated with downregulation of vimentin in human ovarian carcinoma cells.
Kanakkanthara A; Rawson P; Northcote PT; Miller JH
Pharm Res; 2012 Nov; 29(11):3022-32. PubMed ID: 22584948
[TBL] [Abstract][Full Text] [Related]
14. Docking and molecular dynamics studies of the binding between Peloruside A and tubulin.
Liao SY; Mo GQ; Chen JC; Zheng KC
J Enzyme Inhib Med Chem; 2014 Oct; 29(5):702-9. PubMed ID: 24156744
[TBL] [Abstract][Full Text] [Related]
15. Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.
Kanakkanthara A; Eras J; Northcote PT; Cabral F; Miller JH
Curr Cancer Drug Targets; 2014; 14(1):79-90. PubMed ID: 24245693
[TBL] [Abstract][Full Text] [Related]
16. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.
Wilmes A; Bargh K; Kelly C; Northcote PT; Miller JH
Mol Pharm; 2007; 4(2):269-80. PubMed ID: 17397239
[TBL] [Abstract][Full Text] [Related]
17. Peloruside, laulimalide, and noscapine interactions with beta-tubulin.
Gajewski MM; Alisaraie L; Tuszynski JA
Pharm Res; 2012 Nov; 29(11):2985-93. PubMed ID: 22733149
[TBL] [Abstract][Full Text] [Related]
18. Modulation of lateral and longitudinal interdimeric interactions in microtubule models by Laulimalide and Peloruside A association: A molecular modeling approach on the mechanism of microtubule stabilizing agents.
Zúñiga MA; Alderete JB; Jaña GA; Fernandez PA; Ramos MJ; Jiménez VA
Chem Biol Drug Des; 2018 May; 91(5):1042-1055. PubMed ID: 29316292
[TBL] [Abstract][Full Text] [Related]
19. Elucidation of the anticancer potential and tubulin isotype-specific interactions of β-sitosterol.
Pradhan M; Suri C; Choudhary S; Naik PK; Lopus M
J Biomol Struct Dyn; 2018 Jan; 36(1):195-208. PubMed ID: 27960611
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.
Begaye A; Trostel S; Zhao Z; Taylor RE; Schriemer DC; Sackett DL
Cell Cycle; 2011 Oct; 10(19):3387-96. PubMed ID: 21926482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
